- DE EN
- About Us
- Study Participation
The institute’s own device development was discontinued in 2002. Since then, we are working as an independent contract research organization.
With the development of automated insulin dosing systems (AID) during the last years, the dream of Prof. Pfeiffer regarding an artificial pancreas has at least come partially true. We supported manufactures on their way to this goal with clinical studies.
Our core competence lies in the accuracy testing of blood glucose meters according to ISO 15197, the testing of systems for continuous glucose monitoring (CGM) and insulin pumps.
The IfDT is directed by Dr. med. Guido Freckmann, general practitioner and diabetologist. He started his work at the institute in 1999 as an investigator and took over the executive and medical management in 2005. Prof. Dr. med. Cornelia Haug from the central facility of clinical chemistry at the university hospital Ulm is our scientific director.
Our team is composed of medical staff, physicians, medical-technical assistants, dieticians, diabetes advisors, scientists and administrative employees. Thanks to our versatile expertise, we can handle a wide range of scientific questions and requests.
Our status as an associated “An Institute” of the university Ulm enables a close collaboration as well as the use of university facilities.
In 2018, we have moved to our new, modern, spacious rooms located at the science park II in Ulm. Our new rooms are customized perfectly for our requirements as a test center and reference laboratory.
As a test center we want to substantially contribute to the advancement of medical devices and want to assure benefits and safety for the users. For us, the study participants, their safety and well-being are number one priority.
Studies are necessary to gain or expand information about the suitability, the performance and the safety of medical devices. To us, the well-being of people with diabetes and our study participants is particularly important for us. Therefore, on one hand it is very important to us to promote research regarding diabetes technology to improve therapy of the concerned people but on the other hand we always have the risks associated with study participation in mind. Therefore, we only conduct studies which are ethically acceptable.
We stand for competent, reliable, quality-oriented and independent conduction of our studies and our test services. All projects are performed according to the state of the art in science and technology considering legal and normative directions.
Since 2015 we are accredited by the Deutschen Akkreditierungsstelle GmbH (DAkkS / ILAC) and since 2017 also recognized from the Zentralstelle der Länder für Gesundheitsschutz bei Arzneimitteln und Medizinprodukten (ZLG) as a test laboratory according to DIN EN ISO/IEC 17025 and the guideline 98/79/EG for investigations after DIN EN ISO 15197.
All examinations are conducted impartially and independently. We do not offer any services which could jeopardize credibility in our independence, impartiality and objectivity.
As accredited test laboratory according to DIN EN ISO/IEC 17025 we do not offer consultation for manufactures regarding the conception, the construction, the marketing and the maintenance of blood glucose meters (test strips, meters).
The success of our work and the quality of our services are based on the knowledge and the enthusiasm of our employees. The motivation, the involvement and the continuing education of our employees are the base and the drive to develop a quality-conscious and performance-driven corporate culture. Behind the institute there is a competent team whose collaboration is characterized by honesty, team spirit, trust and a familiar, subject-oriented atmosphere.
Based on our professional expertise and our longstanding experience it is possible for us to adjust our services individually and flexibly on the special challenges of each project. Our work is characterized by reliability and accuracy. The requirements and special requests of our customers will be taken into account.
We contribute actively and cooperatively on international level through congress contributions, publications and presentations. With this we do our part in promoting research in diabetes technology. To be able to accommodate the specific requests of our customers, it is very important to always stay up to date and engaged in scientific exchange.
To improve the reader-friendliness of our website, we use the generic masculine. In the context of equal treatment, we would like to point out that the content of our website is aimed at all genders and does not contain any valuation.